Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance

(2022) Maitry Bhardwaj et al.   Cutaneous and Ocular Toxicology

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

(2022) Shun Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review

(2022) Qianqian Zhang et al.   Frontiers in Endocrinology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

(2022) J. Haanen et al.   ANNALS OF ONCOLOGY

Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series

(2022) Xinjing Ding et al.   Oncology Letters

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

(2022) Tetsuya Mitsudomi et al.   Journal of Thoracic Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review

(2021) Longqiu Wu et al.   Annals of Translational Medicine

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events

(2020) Amaris N. Geisler et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Beyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase Inhibitors

(2020) Misako Nagasaka et al.   Journal of Thoracic Oncology

Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer

(2019) Jennifer W Carlisle et al.   Future Oncology

Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis

(2019) Lilan Yi et al.   INTERNATIONAL JOURNAL OF CANCER

Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study

(2019) Basak Yalici-Armagan et al.   Cutaneous and Ocular Toxicology

Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer

(2019) Maria Carmela Annunziata et al.   CLINICAL DRUG INVESTIGATION

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

(2017) M. G. Kris et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

(2016) Glenwood Goss et al.   LANCET ONCOLOGY

Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non–Small Cell Lung Cancer

(2016) Kai-Lung Chen et al.   JAMA Dermatology

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Non–Small Cell Lung Cancer, Version 6.2015

(2015) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

(2011) Mario E. Lacouture et al.   SUPPORTIVE CARE IN CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY